Skip to main content

Hypnotics and sedatives ...New agents in the horizon..part 1


Remimazolam (CNS 7056) is a new benzodiazepine metabolized by tissue esterases so that it has a rapid, more predictable offset of action than other clinically available benzodiazepines. The first clinical studies of remimazolam (CNS 7056) were published recently.
The first phase I study was a relatively compre- hensive, placebo and active midazolam controlled single-dose escalation study in 81 subjects. Ten cohorts of subjects received remimazolam from 0.01 to 0.30 mg/kg, or midazolam 0.075 mg/kg or placebo for comparison. Frequent arterial and venous blood samples were taken for pharmaco- kinetic analysis, and Modified Observer’s Assess- ment of Alertness/Sedation (MOAA/S) scores and bispectral index (BIS) monitoring were used as the main assessments of sedation.
Remimazolam produced rapid dose-dependent sedation at doses from 0.075 mg/kg, with onset times of 1 – 3 min. Remimazolam 0.075 – 0.20 mg/kg produced similar peak sedation to midazolam 0.075mg/kg, but median recovery times at these doses ranged from 5 to 20min, compared with 40min for midazolam. There were three cases of hemoglobin desaturation at higher remimazolam doses, likely reflecting some upper airway obstruction, but no cardiovascular instability or serious adverse events.
Noncompartmental analysis confirmed rapid metabolism, with the mean (SD) clearance of remi- mazolam (70.3 (13.9) l/h) being three times that of midazolam 23.0 (4.5) l/h, the mean residence time of remimazolam (0.51h) seven times less than midazolam (3.6h) and the mean (SD) steady state volume of distribution for remimazolam (34.8 (9.4) l) less than half that of midazolam (81.8 (27.1) l 
The first phase II study of remimazolam was in patients undergoing diagnostic upper gastrointestinal endoscopy .Unfortunately, problems with the study design made it difficult to evaluate some of the results. One hundred patients were randomized in a double-blind manner at seven sites to receive a single dose of remimazolam (0.10, 0.15 or 0.20mg/kg) or midazolam (0.075 mg/kg). Success was achieved in 32%, 56%, 64% and 44% of patients respectively, but success was defined by a composite endpoint. Half of the patients required additional sedation with either midazolam or propofol, and this additional sedation was considered a failure, even though endoscopy was completed in all patients with mean procedure times of 3.3 – 4.3 min. The onset of sedation in the remimazolam groups was 1.5 – 2.5 min compared with 5 min for midazolam. Recovery in the remimazolam groups was 11.0– 13.4 min compared with 17.2 min for midazolam, but the additional sedation given made it difficult to evaluate the effect of remimazolam alone
Bodor N, Buchwald P. Soft drug design: general principles and recent applications. Med Res Rev 2000; 20:58–101. 

Sneyd JR. Remimazolam: new beginnings or just a me-too? Anesth Analg 2012; 115:217


 

Comments

Post a Comment

Popular posts from this blog

power injectable peripherally inserted central catheters

Clinical experience with power injectable peripherally inserted central catheters in intensive care patients     Introduction In intensive care units (ICU), peripherally inserted central catheters (PICC) may be an alternative option to standard central venous catheters, particularly in patients with coagulation disorders or at high risk for infection. Some limits of PICCs (such as low flow rates) may be overcome by the use of power-injectable catheters . Method We have retrospectively reviewed all the power injectable PICCs inserted in adult and pediatric patients in the ICU during a 12-month period, focusing on the rate of complications at insertion and during maintenance. Results We have collected 89 power injectable PICCs (in adults and in children), both multiple and single lumen. All insertions were successful. There were no major complications at insertion and no episodes of catheter-related blood stream infection. Non-infective complications ...
1 comment
Read more

The 12 decision making steps for post dural puncture headache treatment

Treatment decision-making algorithm for postdural puncture headache. 1. When diagnosis is made, all patients should receive supportive measures (reassurance, bed rest, analgesics, hydration, quiet environment). 2. Severity of symptoms should be classified using VAS scale (mild 1–3, moderate 4–6, severe 7–10). 3. Virtually all patients will improve in time even without additional therapy. (dashed lines) 4. Symptoms worsen or fail to resolve within 5 days. 5. Patient preference dictates the choice between pharmacologic (less effective) and epidural blood patch (EBP). 6. In patients with severe symptoms, EBP is strongly suggested. 7. The most common pharmacologic measure is  caffeine  prescription. 8. The failure, worsening, or recurrence of symptoms after pharmacologic measures favors the use of EBP. 9. In addition to EBP, other epidural treatment options can be considered in select patients (eg,  dextran , saline). 10. A period of 24 h should lapse before repeating EBP. 11...
1 comment
Read more

Things to Avoid in Anesthesia for Pregnant with Pulmonary hypertension

Anesthesia for Pregnant woman with Pulmonary Hypertension is a real challenge for anesthesiologist. It is very crucial to remember the pathophysiology of pulmonary hypertension in pregnant women and to avoid some practices that will worsen the cardiac status. 1-Avoid single shot spinal anesthesia. Some authorities consider pulmonary hypertension as absolute contraindication for single shot spinal anesthesia specially in patients with NYHA III ,IV. Spinal anesthesia causes major hemodynamic instability(decrease SVR, decrease VR, decrease in CO) The preferred neuroaxial techniques are (epidural anesthesia and CSE with minimal spinal dose) 2-Avoid PAC. Pulmonary Artery catheters insertion may lead to pulmonary artery rupture or thrombosis. TEE is better cardiac monitor/Arteial line is mandatory. 3-Avoid Nitrous oxide in gas mixture.N2O increase the PVR 4-If MV to be started, avoid High TV and PEEP 5-Avoid Oxytocin Boluses, or rapid administration of Pitocin. Oxytocin causes ...
Post a Comment
Read more